TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
TG Therapeutics reported Q1 2026 revenue of approximately $205 million, up 71% year-over-year, with BRIUMVI U.S. net product revenue of $194.8 million representing 63% quarterly growth. Net income came in at $19.8 million, or $0.12 per share, compared to $5.1 million in the prior year. Based on the strong start to 2026, the company raised full-year 2026 guidance for total global revenue to approximately $925 million and BRIUMVI U.S.
Key figures
- Eps
- 0.12
- Revenue
- 204918000
- Guidance
- FY2026 total global revenue ~$925M; BRIUMVI U.S. net product revenue $885-900M (raised from $825-850M); Q2 BRIUMVI U.S. net revenue ~$220M
- Net income
- 19777000
- Cash position
- 572835000
- Briumvi revenue
- 194800000
- Non dilutive capital
- 500000000
- Buyback authorization
- 300000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.